Skip to main content
SpringerLink
Log in

Therapeutische Probleme bei der Behandlung des v.-Willebrand-Syndroms

  • Conference paper
23. Hämophilie-Symposion

  • 26 Accesses

Zusammenfassung

Im Vordergrund der Behandlung von Blutungsepisoden des v.-Willebrand-Syndroms (vWS) steht der Vasopressinabkömmling DDAVR Beim schweren vWS vom Typ-III- oder bei Typ-I- oder II-Patienten, die nicht auf DDAVP ansprechen, wird jedoch gelegentlich eine Substitution mit Plasmaprodukten erforderlich. Hierzu stehen unterschiedliche F-VIII-Konzentrate zur Verfügung, von denen einige Eigenschaften aufweisen, die für die Behandlung des vWS von besonderer Bedeutung sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F (1992) Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 79:3130–3137

    PubMed  CAS  Google Scholar 

  2. Aledort LM (1991) von Willebrand’s disease: a therapeutic challenge. Biomedical Progress 4:43

    Google Scholar 

  3. Berntorp E, Nilsson IM (1989) Use of a high-purity Factor VIII concentrate (Hemate P) in von Willebrand’s disease. Vox Sanguinis 56:212–217

    Article  PubMed  CAS  Google Scholar 

  4. Scharrer I (1991) The treatment of von Willebrand’s disease. In: Lusher JM, Kessler CM (Hrsg) Hemophilia and von Willebrand’s Disease in the 1990’s. Amsterdam, New York, Elsevier Science Publishers B.V., pp 463–469

    Google Scholar 

  5. Fukui H, Nishino M, Terada S et al. (1988) Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand’s disease. Blut 56:171–178

    Article  PubMed  CAS  Google Scholar 

  6. Czapek EE, Gadarowsky JJ, Ontiveros JD, Pedraza JL (1988) Humate P for treatment of von Willebrand’s disease. Blood 72:1100

    PubMed  CAS  Google Scholar 

  7. Schimpf K, Mannucci PM, Kreuz W et al. (1987) Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 316:918

    Article  PubMed  CAS  Google Scholar 

  8. Köhler M, Hellstern P, Wenzel E (1985) The use of heat-treated factor VIII-concentrates in von Willebrand’s disease. Blut 50:25–27

    Article  PubMed  Google Scholar 

  9. Scharrer I (1985) Einführung: Zur Therapie des von Willebrand Syndroms. In: Landbeck G, Marx R (Hrsg) 16. Hämophilie-Symposion Hamburg, S 211–217

    Google Scholar 

  10. Blatt PM, Brinkhous KM, Culp HR et al. (1976) Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding time factor and ristocetin-cofactor activities. JAMA 236:2770–2772

    Article  PubMed  CAS  Google Scholar 

  11. Dent JA, Berkowitz SD, Ware J et al. (1990) Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87:6306–6310

    Article  PubMed  CAS  Google Scholar 

  12. Ginsburg D, Konkle BA, Gill JC et al. (1989) Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci USA 86:3723–3727

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Aygören
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Vigh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Scharrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Angiologie, Universitätsklinikum, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Inge Scharrer

  2. Hämostaseologische Abteilung, Med. Univ.-Klinik Innenstadt, Ziemssenstraße 1a, D-80336, München, Germany

    Wolfgang Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Aygören, E., Vigh, Z., Scharrer, I. (1993). Therapeutische Probleme bei der Behandlung des v.-Willebrand-Syndroms. In: Scharrer, I., Schramm, W. (eds) 23. Hämophilie-Symposion. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78359-3_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78359-3_48

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56955-8

  • Online ISBN: 978-3-642-78359-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation